EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Perioperative antihypertensive medication use is associated with no antifibrotic benefit but higher complications and revision rates following shoulder arthroplasty

Tarishi Parmar, Miguel Fiandeiro, Mohammad Daher, Akin Adio, Jad Lawand, Adam Khan, Joseph Abboud

European Journal of Orthopaedic Surgery & Traumatology · 2026

DOI: 10.1007/s00590-026-04883-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Orthopaedic Surgery & Traumatology, 2026. Verfasst von Tarishi Parmar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Shoulder and Elbow Surgery, Rothman Orthopaedics, Philadelphia, USA. txp539@students.jefferson.edu. Hauptthemen laut MEDLINE: Reoperation, Postoperative Complications, Arthroplasty, Replacement, Shoulder, Angiotensin-Converting Enzyme Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Renin-angiotensin-aldosterone system (RAAS) inhibitors, including angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs), are commonly prescribed antihypertensive medications with proposed antifibrotic and bone-protective effects. Their impact on outcomes following total shoulder arthroplasty (TSA) remains unclear. This study evaluates the association between perioperative RAAS inhibitor exposure and postoperative outcomes after TSA.

Methods

A retrospective cohort study using the TriNetX network identified patients undergoing primary shoulder arthroplasty (2005–2025), stratified by ACEi or ARB use. One-to-one propensity score matching was performed. Outcomes included 90-day medical complications and 1-year mechanical complications and revision.

Results

Post-matching, 27,938 patients per cohort (ARB vs. control) and 30,602 per cohort (ACEi vs. control) were included. Neither ARB nor ACEi use reduced rates of manipulation under anesthesia or capsular release at one year. Both cohorts had higher 90-day rates of emergency department visits, readmission, myocardial infarction, and acute renal failure. ACEi use was additionally associated with pulmonary embolism, deep-vein thrombosis, transfusion, and sepsis. At one year, both cohorts showed higher rates of periprosthetic joint infection, aseptic loosening, and revision. Dislocation risk was increased with ACEi use only.

Conclusion

Perioperative RAAS inhibitor use was not associated lower rates of antifibrotic procedures following TSA. Instead, RAAS inhibitor use was associated with higher rates of several perioperative medical complications and longer-term surgical events, including infection and revision. ACE inhibitor exposure demonstrated a broader complication profile compared with ARB exposure. However, because patients receiving RAAS inhibitors often have greater comorbidity burden, these findings should be interpreted as associative rather than causal. Level of evidence III Retrospective Cohort Study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ReoperationPostoperative ComplicationsArthroplasty, Replacement, ShoulderAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsAngiotensin Receptor AntagonistsHumansRetrospective StudiesFemaleMaleAgedMiddle AgedPerioperative Care

Stichwörter der Autor:innen

Angiotensin receptor blockersAngiotensin-converting enzyme inhibitorsFibrosisPostoperative complicationsRenin-angiotensin-aldosterone system inhibitorsTotal shoulder arthroplasty

Substanzen

Angiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • Division of Shoulder and Elbow Surgery, Rothman Orthopaedics, Philadelphia, USA. txp539@students.jefferson.edu.
  • Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
  • Division of Shoulder and Elbow Surgery, Rothman Orthopaedics, Philadelphia, USA.
  • John Sealy School of Medicine, The University of Texas Medical Branch at Galveston, Galveston, USA.
  • Department of Orthopedic Surgery, Southern California Permanente Medical Group, Panorama City, USA.

Zitieren

APA

Parmar, T., Fiandeiro, M., Daher, M., Adio, A., Lawand, J., Khan, A., & Abboud, J. (2026). Perioperative antihypertensive medication use is associated with no antifibrotic benefit but higher complications and revision rates following shoulder arthroplasty. European Journal of Orthopaedic Surgery & Traumatology. https://doi.org/10.1007/s00590-026-04883-y

Vancouver

Parmar T, Fiandeiro M, Daher M, Adio A, Lawand J, Khan A, et al. Perioperative antihypertensive medication use is associated with no antifibrotic benefit but higher complications and revision rates following shoulder arthroplasty. European Journal of Orthopaedic Surgery & Traumatology. 2026. doi:10.1007/s00590-026-04883-y

BibTeX
@article{Parmar2026,
  author = {Parmar, Tarishi and Fiandeiro, Miguel and Daher, Mohammad and Adio, Akin and Lawand, Jad and Khan, Adam and Abboud, Joseph},
  title = {Perioperative antihypertensive medication use is associated with no antifibrotic benefit but higher complications and revision rates following shoulder arthroplasty},
  journal = {European Journal of Orthopaedic Surgery & Traumatology},
  year = {2026},
  doi = {10.1007/s00590-026-04883-y}
}
Kostenlos starten →